We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

CerTest to Run ‘More than Diagnostics’ Campaign Throughout 2023

By LabMedica International staff writers
Posted on 01 Feb 2023

The world is currently experiencing a change of era. Even as it still emerging from the SARS-CoV-2 pandemic, there are new unexpected challenges that must be met. For CerTest Biotec (Zaragoza, Spain), the recent years of the pandemic have been a turning point that have made it a better company in every sense. CerTest has demonstrated that under extreme conditions, it has the ability to work towards achieving a common goal, offer a befitting response to the extraordinary circumstances and, instill confidence among its customers, suppliers and partners.

CerTest has now announced that the company will run its campaign ‘More than Diagnostics’ throughout 2023 in acknowledgement of the transformation that it has gone through, accelerated by the COVID-19 pandemic. CerTest’s ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future, with people’s health remaining its key focus.


Image: The ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future (Photo courtesy of CerTest)
Image: The ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future (Photo courtesy of CerTest)

CerTest remains optimistic about the future and is well aware of the need to sustain its efforts and to continue backing the four concepts which have defined the company right from the start - service, responsibility, confidence and research. Over the coming period, CerTest plans to employ more people, build more facilities, increase its R&D activities, and come up with more products and solutions that are better as well as more effective.

Related Links:
CerTest Biotec 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Latest Industry News

ECCMID Congress Name Changes to ESCMID Global

Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform

Siemens to Close Fast Track Diagnostics Business